Hyloris is on a roll with licensing deals for its Maxigesic IV non-opioid pain treatment, with an extension of its existing agreement with Pharma Bavaria to cover South American territories coming hot on the heels of recent developments in the US and Europe.
Belgian value-added medicines specialist Hyloris Pharmaceuticals has announced yet another licensing deal for its Maxigesic IV (paracetamol/ibuprofen) 1,000mg/300mg intravenous analgesic, extending a deal initially struck with Pharma Bavaria International in 2020 for Central America to cover Latin America and the Caribbean.
The February 2020 deal with Pharma Bavaria covered the commercialization of Maxigesic IV in 12 countries in Central America, while...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
